| Acute myeloid leukemia and artificial intelligence, algorithms and new scores N Radakovich, M Cortese, A Nazha Best practice & research. Clinical haematology 33 (3), 101192, 2020 | 23 | 2020 |
| Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review LL George, SR Deshpande, MJ Cortese, EK Kendall, A Chattaraj, Z Shah, ... Clinical Lymphoma Myeloma and Leukemia 21 (11), 741-751, 2021 | 8 | 2021 |
| Actin dosage lethality screening in yeast mediated by selective ploidy ablation reveals links to urmylation/wobble codon recognition and chromosome stability B Haarer, L Mi-Mi, J Cho, M Cortese, S Viggiano, D Burke, D Amberg G3: Genes, Genomes, Genetics 3 (3), 553-561, 2013 | 5 | 2013 |
| A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma MJ Cortese, W Wei, S Cerdeña, MP Watkins, M Olson, G Jodon, J Kaiser, ... Leukemia & Lymphoma 64 (1), 107-118, 2023 | 4 | 2023 |
| Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy M Melody, N Epperla, G Shouse, J Romancik, P Allen, TK Moyo, V Kenkre, ... Blood Advances 8 (10), 2327-2331, 2024 | 3 | 2024 |
| Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in … ML Palomba, MG Mei, PF Caimi, M Cortese, M Davila, G Yadnik, N Huang, ... Cancer Research 83 (8_Supplement), CT125-CT125, 2023 | 3 | 2023 |
| The age, comorbidities and albumin (ACA) index is independently associated with overall survival in patients with mantle cell lymphoma (MCL) OS Akhtar, A Anampa-Guzman, MJ Cortese, A Taneja, S Ba Aqeel, ... Blood 140 (Supplement 1), 5160-5161, 2022 | 2 | 2022 |
| A “CRISPR” non-viral manufacturing approach for CAR T cell therapies MJ Cortese, C Sauter Molecular Therapy 30 (11), 3338-3340, 2022 | 2 | 2022 |
| Severe thrombocytopenia in a patient with otherwise asymptomatic COVID-19. LM Granat, AD Singh, M Cortese, V Velez, A Lichtin Cleveland Clinic Journal of Medicine 88 (2), 86-92, 2021 | 2 | 2021 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024 WG Wierda, J Brown, JS Abramson, F Awan, SF Bilgrami, G Bociek, ... Journal of the National Comprehensive Cancer Network 22 (3), 175-204, 2024 | 1 | 2024 |
| Antigen-Specific T-Cell Repertoire Responses Following COVID-19 Vaccination Are Intact in Majority of Patients with B-Cell Lymphoid Malignancies on Active Therapy S Goel, EA Griffiths, B Segal, M Nemeth, MJ Cortese, ... Blood 142, 5714, 2023 | 1 | 2023 |
| Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy TK Mandeville, C Mavis, J Gu, K Bowman, S Olejniczak, P Dey, G Paragh, ... Blood 142, 6845, 2023 | 1 | 2023 |
| Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: A National Cancer Database study VM Rogness, W Wei, M Cortese, BT Hill Leukemia research 134, 107402, 2023 | 1 | 2023 |
| Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma MA Sohail, H Li, W Wei, S Cerdena, M Watkins, M Olson, G Jodon, ... Blood 136, 24-25, 2020 | 1 | 2020 |
| Outcomes of Active Surveillance Versus Initial Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients MJ Cortese, W Wei, BT Hill Blood 136, 29-30, 2020 | 1 | 2020 |
| A multi-center analysis of the impact of dose level of R-EPOCH on outcomes of patients with double/triple-hit B-Cell Lymphoma MJ Cortese, W Wei, S Cerdena, M Watkins, M Olson, G Jodon, J Kaiser, ... Blood 136, 32-34, 2020 | 1 | 2020 |
| Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R … M Amin, A Niu, K Attwood, A George, F Azad, J Wong, G Schofield, ... Journal of Clinical Oncology 42 (16_suppl), 7042-7042, 2024 | | 2024 |
| Treatment Selection and Clinical Outcomes in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia (LPL/WM)-a Single Center Analysis MJ Tariq, AC Anampa-Guzmán, M Alharbi, K Shalaby, R Patel, S Hamid, ... Blood 142, 4421, 2023 | | 2023 |
| Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities M Melody, N Epperla, MJ Cortese, JT Romancik, TK Moyo, VP Kenkre, ... Blood 142, 2407, 2023 | | 2023 |
| Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 US Academic Centers T Voorhees, E McLaughlin, P Torka, JA Florindez, TK Moyo, H Reves, ... Blood 142, 3061, 2023 | | 2023 |
Pallawi TorkaMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
